Background. Monitoring of mycophenolic acid (MPA) levels may be useful for effective mycophenolate mofetil (MMF) dosing. However, whether commonly obtained trough levels are an acceptable method of surveillance remains debatable. We hypothesized that trough levels of MPA would be a poor predictor of area under the curve (AUC) for MPA. Methods. A total of 51 patients with lupus nephritis who were on MMF 1500 mg twice a day and had a 4-h AUC done were included in this study. MPA levels were measured prior to (C0) and at 1 (C1), 2 (C2) and 4 (C4) h, followed by 1500 mg of MMF. The MPA AUC values were calculated using the linear trapezoidal rule. Regression analysis was used to examine the relationship between the MPA trough and AUC. Differences in the MPA trough and AUC between different clinical and demographic categories were compared using t-tests. Results. When grouped by tertiles there was significant overlap in MPA, AUC 0-4 and MPA trough in all tertiles. Although there was a statistically significant correlation between MPA trough levels and AUC, this association was weak and accounted for only 30% of the variability in MPA trough levels. This relationship might be even more unreliable in men than women. The use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with increased MPA trough levels and AUC at 0-4 h (AUC 0-4 ). Conclusion. Trough levels of MPA do not show a strong correlation with AUC. In clinical situations where MPA levels are essential to guide therapy, an AUC 0-4 would be a better indicator of the adequacy of treatment.
I N T R O D U C T I O N
Lupus nephritis is one of the most serious manifestations of systemic lupus erythematosus (SLE), affecting >50% of patients with SLE [1] . While mycophenolate mofetil (MMF) therapy is commonly used to attain clinical remission [2, 3] , relapses following initial remission are prevalent in patients with proliferative lupus nephritis [4] [5] [6] [7] [8] , often requiring maintenance therapy with MMF. Although well tolerated and relatively safe, longterm use of MMF is associated with gastrointestinal side effects as well as risks of immunosuppression [9] . Therefore, establishing and targeting well-defined therapeutic levels is important to optimize clinical outcomes while limiting exposure to MMF and minimizing side effects.
Previous studies have shown that the area under the curve for plasma concentration-time of mycophenolic acid (MPA), the active moiety of MMF from 0 to 12 h (AUC 0-12 ), is associated with favorable clinical outcomes [10] . Recent small, uncontrolled trials have suggested that a patient-tailored therapy based on therapeutic drug monitoring of MPA can improve clinical outcomes in patients with lupus nephritis [11] [12] [13] . Based on the available literature, an MPA AUC 0-12 of 30-90 mg*h/L [11, [13] [14] [15] [16] [17] and/or a therapeutic trough level between 3 and 4.5 mg/L [18, 19] is recommended to decrease the risk of treatment failure in patients with lupus nephritis treated with MMF.
However, MPA AUC 0-12 is cumbersome and expensive to perform. An abbreviated MPA AUC over 0-4 h (AUC 0-4 ) correlates reasonably with the full AUC (r ¼ 0.87, P < 0.001) [20] and predicts total MPA exposure [21, 22] in transplant patients. Nevertheless, most clinicians routinely only obtain trough levels of MPA, which, at least in transplant recipients, does not adequately reflect exposure to MPA [23, 24] , due to the wide interindividual variability. Variability may even be more of a challenge in patients with lupus, who often have increased inflammatory markers, hypoalbuminemia and renal dysfunction [25] , all of which can affect MMF levels. However, the relationship between trough levels and MPA AUC has not been studied. We hypothesized that trough levels of MPA would be a poor predictor of MPA AUC in patients with lupus nephritis. The purpose of our study was to examine the correlation of MPA AUC 0-4 and trough levels of MMF in patients with lupus nephritis.
M A T E R I A L S A N D M E T H O D S

Data source and participants
The study was approved by the Institutional Review Board at the University of Florida. A retrospective analysis was performed on a cohort of 51 patients diagnosed with biopsyproven lupus nephritis who received their care at the University of Florida between 25 July 2008 and 16 August 2016. All patients were receiving a fixed dose of MMF 1500 mg twice a day, as induction/maintenance therapy of their underlying disease, and had MPA AUC 0-4 and trough levels determined as a part of their routine clinical care. For assaying, MPA AUC 0-4 blood samples were collected from subjects at four time points [0 (predose, C 0 ) and 1 (C 1 ), 2 (C 2 ) and 4 (C 4 ) h postdose] and MPA plasma concentrations were measured using high-performance liquid chromatography. The MPA AUC 0-4 was calculated using the linear trapezoidal rule [26] . Medical records were reviewed to abstract demographic and clinical characteristics, including the medical treatment received and renal function. We used standardized reference serum creatinine, gender, race and age to calculate a reference estimated glomerular filtration rate (eGFR) based on the Modification of Diet in Renal Disease equation [27] . The degree of proteinuria was determined by the random urine albumin:creatinine ratio (in mg/mg). All serum and urine chemistries and immunoassays were performed in the central hospital clinical laboratory or Quest referral laboratories.
Statistical analysis
Continuous variables, if normally distributed, were reported as mean 6 standard deviation and compared using independent t-test and if normalcy assumptions were not met, presented as median 6 interquartile range and compared by Mann-Whitney U-test. Categorical variables were presented as frequency and percentage and compared using chi-square or Fisher's exact test. Spearman's rank correlation analyses were performed to examine the unadjusted association between MPA AUC and trough levels. Multivariate regression analyses were employed to control for other potential confounding factors. Normality was examined for linear regression analysis. Significance tests were two-sided, with a P-value <0.05 considered statistically significant. All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).
R E S U L T S
The study included a total of 51 patients ranging from 15 to 62 years of age, with a mean age of 33 years. They were predominantly of Caucasian descent [35 of 51 patients (68.6%)] and female (with a male:female ratio of 3:10). All patients had World Health Organization (WHO) Class III or higher lupus nephritis at the time of presentation. At the time of analysis, everyone was being treated with MMF 1500 mg twice a day for management of lupus nephritis. Along with MMF, patients were on steroids and/or Plaquenil. Among all the patients, 45% were on Plaquenil only, 22% were on only steroids and 34% were on both Plaquenil and steroids. Of the cohort, 90% of patients were on one or more antihypertensive drugs at the time of treatment for lupus nephritis: 86% were on either angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and 53% were prescribed diuretics. At the time of the MPA AUC measurement, only three patients were determined to have nephrotic syndrome and only two had an eGFR level <15 mL/min/1.73 m The relationship between the MPA trough and AUC 0-4 levels with clinical variables is shown in Figure 2 . The MPA trough and AUC 0-4 levels did not differ between races. The mean MPA trough level was 3.3 6 3.1 mg/L for African Americans and 4.0 6 3.4 mg/L for Caucasians (P ¼ 0.48), whereas the mean MPA AUC 0-4 level was 53.0 6 23.7 mg*h/L for African Americans and 66.6 6 36.4 mg*h/L for Caucasians (P ¼ 0.19). Also, there was no significant difference in MPA trough levels or MPA AUC 0-4 levels between males and females. The mean MPA trough level was 5.2 6 3.8 mg/L in males and 3.4 6 3.1 mg/L in females (P ¼ 0.11), whereas the mean MPA AUC 0-4 level was 54.8 6 22.4 mg*h/L in males and 64.4 6 35.6 mg*h/L in females (P ¼ 0.42). However, while the trough levels were lower in females than males, the AUC levels were higher in women than in men. An interaction analysis showed that there was a strong interaction between gender and trough levels in determining AUC 0-4 levels (P ¼ 0.009). When comparing smokers with nonsmokers, trough levels and MPA AUC 0-4 levels were not different between the two groups (P ¼ 0.75 and P ¼ 0.76, respectively). Neither was a significant difference noted between MPA AUC 0-4 and trough levels in patients with hypertension (HTN), diabetes mellitus (DM) or hyperlipidemia compared with those patients who did not have these comorbidities (P ¼ 0.36, 0.99 and 0.92 for trough levels and P ¼ 0.73, 0.60 and 0.19 for MPA AUC, respectively).
We also compared the relationship of MPA trough and MPA AUC 0-4 levels with concurrent medication use, including Plaquenil, steroids, ACE inhibitors and diuretics, as shown in Figure 3 . Our study revealed that there were no statistically significant differences in MPA AUC 0-4 levels with the concurrent use of steroids, Plaquenil or diuretics (P ¼ 0.12, 0.46 and 0.93, respectively). Moreover, concomitant use of steroids, Plaquenil and diuretics did not cause a significant change in MPA trough levels (P ¼ 0.78, 0.53 and 0.20, respectively). However, concurrent ACE inhibitor/ARB use resulted in increased MPA AUC 0-4 and trough levels (P ¼ 0.04 and 0.01, respectively).
D I S C U S S I O N
Our results demonstrate that although there was a statistically significant correlation between the trough levels of MPA and MPA AUC 0-4 (r ¼ 0.55, P < 0.001), trough levels only explained 30% of the variance in AUC 0-4 and all tertiles of trough levels showed significant overlap of MPA AUC 0-4 levels.
There have been several small studies on MPA pharmacokinetics in patients with SLE [19] . Our findings are at odds with those of Lertdumrongluk et al. [11] showing that, the plasma trough concentration of MPA 0-12 significantly correlated with the AUC 0-12 (r ¼ 0.90, P < 0.05) and was associated with response to MMF therapy. However, their study was small, with only 18 subjects, all of whom were Asian. Our results are consistent with Alexander et al. [17] who studied a small cohort of patients from Inidia with proliferative lupus nephritis, and found only a weak correlation between trough levels and MPA AUC 0-12 , with only 31% of the variance in AUC explained by the trough levels. Similarly, Neumann et al. [18] showed a weak, but significant, correlation between 12-h trough MPA concentrations and MPA AUC 0-12 (r ¼ 0.578; P < 0.05) in patients with autoimmune diseases including lupus nephritis. However, only 12 of these patients had lupus. A detailed review of published studies over the past 15 years that have addressed the relationship between blood levels, the method of measuring MMF and clinical outcomes is shown in Table 2 . To the best of our knowledge, our study is the largest study in lupus nephritis and the only one to include patients whose demographic makeup is characteristic of the USA and all of whom had biopsy-confirmed lupus nephritis.
We found a significant interaction between gender, AUC 0-4 and trough levels. In women, MPA trough levels were lower but, surprisingly, AUC levels were higher. Although a few small studies have looked at the effect of gender on MPA pharmacokinetics, they have found conflicting results [33] . A recent study by Tornatore et al. [34] looked at the influence of sex and race on MPA pharmacokinetics in renal transplant patients. The authors found no significant difference in 12-h MPA AUC or 12-h trough levels. However, they did find that females had slower MPA clearance and more severe gastrointestinal side effects. Pescovitz et al. [35] showed that in renal transplant patients, the mean concentration time profiles of MPA in the male versus female subjects were very similar when dosed by race and gender. However, they did not study the correlation between trough and AUC. Our study suggests that using trough levels to predict AUC might be even more unreliable in men than women. However, we only had 12 male subjects. Thus further studies with more male patients are needed before making definite conclusions about how gender influences the ability of trough levels to predict MPA.
We did not find any significant correlation between MPA trough and AUC 0-4 concentrations in smoking, diabetes, hyperlipidemia or HTN (Figure 2 ). Previous studies have also 
Error bars depict the standard deviation. suggested that the MPA AUC and trough levels are not influenced by patient-specific factors [36] [37] [38] . Monitoring of MMF exposure in lupus nephritis is made more challenging because of the use of diverse concomitant medications [18, 39] . We found no significant difference in AUC 0-4 or trough levels between patients on steroids or Plaquenil. It should be noted, however, that the available literature on the effect of corticosteroids on MPA AUC is controversial, with one study showing no effect and another demonstrating lower MPA exposure [33, [40] [41] [42] . An incidental finding in our study was that among all the medications, concurrent use of ACE inhibitors/ARBs was noted to have a correlation with increased MPA trough and AUC 0-4 levels. A thorough search of the literature did not reveal any evidence of an interaction between ACE inhibitors/ARBs and MMF, that explains the increase in MMF exposure. However, there is some evidence that a change in renal function and albumin (both of which may be affected by ACE inhibitors/ARBs) may affect MMF exposure [33] . van Hest et al. [33] performed a population pharmacokinetic meta-analysis of MPA in renal transplant recipients to explore potential determinants of total MPA exposure. Among other things, they found that exposure to total MPA significantly increased with decreasing renal function, especially when GFR was <25 mL/min. Changes in renal function above the 25 mL/min threshold for GFR had a minimal effect on MPA clearance. We did not find a significant association between renal function and MPA clearance, possibly because most patients in our cohort had an eGFR >25 mL/min. In addition, an increase in albumin level was significantly associated with increasing MPA exposure. In healthy patients, MPA binds extensively to albumin (97-99%) [19] . A decrease in albumin level can cause an increase in the MPA free fraction and clearance. Acidosis, uremia and accumulation of MPA-7-Oglucuronide (an inactive glucuronide metabolite), all of which are associated with impaired renal function, can also decrease MPA binding to albumin [43] and result in increased clearance. ACE inhibitors and ARBs have been shown to decrease urinary excretion of protein (albumin) and slow the progression of kidney disease [44] [45] [46] . Therefore, in patients receiving MMF, concomitant use of an ACE inhibitor or ARB may be associated with a higher serum albumin level than in those who do not take ACE inhibitors/ARBs, which may decrease the clearance of MPA and thereby increase MPA exposure. In our study, there were no significant differences in serum albumin levels between those patients who received ACE inhibitors or ARBs and those who did not (3.2 versus 3.7; P ¼ 0.2). Also, in reviewing the pharmacokinetics of MPA, one possible mechanism is that a minor MPA metabolite, acyl mycophenolic acid glucuronide (Ac-MPAG) is partially eliminated in the urine. One of the commercially available assays (Thermo Fisher Scientific, Waltham, MA, USA) for detecting MPA in human plasma also demonstrates cross-reactivity with the minor Ac-MPAG metabolite. It is possible that small changes in GFR, seen with ACE inhibitors and ARBs, could result in a small decrease in renal elimination of the Ac-MPAG metabolite. If this particular assay is used to measure the drug level, this could result in a minor increase in the reported blood concentration of MPA. However, the University of Florida and Quest Clinical laboratories use the Roche Diagnostics (Basel, Switzerland) assay, which does not demonstrate significant cross-reactivity with the Acy-MPAG metabolite. Therefore, this explanation is not applicable.
The limitations of this study are the retrospective nature of the study and the relatively small sample size. Also, all of our patients were on a fixed oral dose of 1500 mg twice a day of MMF and the majority were on Plaquenil and/or corticosteroids. In order to assess the pharmacokinetics of MMF, different dosing regimens without the confounding effect of concomitant medications would be ideal. Moreover, the pharmacokinetic profiles of MPA were assessed only once during the 3-to 6-month period and do not assess within-patient variability. Multiple blood samplings for MPA AUC may give us an idea of within-patient variability, but frequent measurements of MPA levels in clinical practice is not cost effective or feasible. However, our pragmatic study is the largest thus far of the pharmacokinetics of MMF in patients with biopsy-confirmed lupus nephritis and reflects real-world conditions under which MMF is likely to be used in lupus nephritis.
C O N C L U S I O N
Studies suggest that clinical outcomes might be optimized by targeting MMF to defined targets rather than using fixed-dose regimens. Clinicians routinely obtain MMF trough levels to guide therapeutic choices. Our study suggests that trough levels do not correlate with the AUC and an abbreviated AUC 0-4 can and must be obtained in all patients to guide MMF dosing. Larger randomized clinical trials are required to evaluate the effect of using MPA AUC 0-4 to impact clinical outcomes in patients with lupus nephritis. 
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